Aldeyra Therapeutics Inc

NASDAQ:ALDX  
3.78
+0.12 (+3.28%)
Products, Regulatory

Aldeyra Therapeutics Announces Positive Top-Line Data From Phase 2 Dry Eye Chamber Clinical Trial Of Reproxalap, An Investigational New Drug, Compared To Xiidra

Published: 01/11/2022 14:15 GMT
Aldeyra Therapeutics Inc (ALDX) - Aldeyra Therapeutics Announces Positive Top-line Data From Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®.
Aldeyra Therapeutics Inc - Reproxalap Statistically Lower Than Xiidrafor Two Endpoints of Trial.
Aldeyra - Results Consistent With Data From Post-acute Ocular Tolerability Comparison of Reproxalap, Xiidra in Patients With Dry Eye Disease.